Understanding TMS-induced Heart-Brain Coupling
Transcranial magnetic stimulation (TMS) is a noninvasive therapy for major depressive disorder (MDD). It works by using magnetic pulses to activate brain regions tied to mood regulation. While TMS is widely used, response rates can vary greatly. One of the biggest challenges is making sure the treatment hits the right brain networks in each individual.
This is where TMS-induced heart-brain coupling (HBC) comes in. HBC measures changes in heart rate that occur when TMS stimulates the prefrontal cortex. These changes reflect communication between the brain and the vagus nerve, which connects the brain to the body. Essentially, HBC provides a physiological “readout” of how well TMS is engaging key mood-related brain circuits.
New Evidence from Clinical Data
A recent study tested whether TMS-induced heart-brain coupling could predict which patients would benefit most from treatment. Researchers followed 101 patients with depression who underwent HBC testing before starting a full TMS course. The study examined heart rate changes across different stimulation intensities and brain targets.
By session 15 of treatment, early responders—patients who showed at least 50 percent symptom reduction—also showed stronger HBC compared to non-responders. This effect was especially clear at stimulation intensities close to actual treatment strength. Patients with strong HBC at higher intensities had nearly triple the likelihood of early improvement compared to those without it.
Why Heart-Brain Coupling Matters
These findings suggest that TMS-induced heart-brain coupling could serve as a valuable biomarker. If clinicians can measure HBC before treatment, they may be able to predict response, select the best brain target, and fine-tune dosing. This represents a major step forward compared to current methods, which mostly rely on motor thresholds that may not reflect brain excitability in mood networks.
HBC also has practical advantages. The assessments take less than an hour, require minimal training, and use affordable wearable technology. Results are available immediately, allowing clinicians to quickly adapt treatment strategies.
Toward Personalized TMS Therapy
Personalization is key in interventional psychiatry. Not every patient responds to the same stimulation site or intensity. Using HBC as a guide, clinicians could perform a quick scan across different prefrontal targets, selecting the one that produces the strongest signal at the lowest dose. This could improve both response rates and patient comfort by avoiding unnecessary overstimulation.
At the same time, the study highlights important considerations. Older patients tended to show weaker HBC overall, raising questions about age-related differences in vagal and brain responsiveness. Future research will need to clarify how HBC fits into broader treatment personalization, especially in diverse patient populations.
The Road Ahead
The link between TMS-induced heart-brain coupling and antidepressant response provides early but promising evidence that physiological markers can guide clinical care. While these findings need confirmation in larger, randomized trials, they point toward a future where TMS is not just standardized but truly tailored to each patient’s brain and body.
For patients with depression, this means treatments may become faster, more effective, and more precise. For clinicians and researchers, it opens a path to integrating simple, scalable tools like HBC into everyday practice—helping to bridge the gap between advanced neuroscience and real-world psychiatry.
References
- Dijkstra, E.S.A., Rouwhorst, R., Zwienenberg, L., et al. (2025). TMS-induced heart-brain coupling associated with early clinical response in depression. Brain Stimulation. https://www.brainstimjrnl.com/article/S1935-861X(25)00336-5/fulltext
- Fox, M.D., Buckner, R.L., White, M.P., Greicius, M.D., Pascual-Leone, A. (2012). Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biological Psychiatry, 72(7), 595–603. https://www.biologicalpsychiatryjournal.com/article/S0006-3223(12)00411-8/abstract